ReviewCellular and molecular gastroenterology and hepatology2023
In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations.
Review in Cellular and molecular gastroenterology and hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Engineered protein nanoclusters reduce liver fibrosis and hepatocellular carcinoma in mice models.Bioactive materials · 2026Article
- Vildagliptin attenuates the development of CCl₄-induced liver fibrosis: associations with gut-liver axis modulation and LPS/notch-related signaling.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Detoxifying Effects of a Phenolic-RichInternational journal of molecular sciences · 2026Article
- GPI: A pan-cancer biomarker integrating genetic alterations, immune infiltration, and therapeutic response prediction.Global medical genetics · 2026Article
- Article
- Article
- 3D Liver Fibrosis Models in Lab: A Novel Modality for Drug Screening.Pharmacology research & perspectives · 2026Review
- Taohong Huazhuo decoction alleviates carbon tetrachloride-induced hepatic fibrosis in rats by inhibiting the nicotinamide adenine dinucleotide phosphate oxidase 4/nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 signaling pathway.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Article
- Ellagic acid from the traditional Chinese medicinal herb Scutellaria barbata may accelerates apoptosis in hepatic stellate cells during liver fibrosis via inhibiting miR-182-5p.Molecular and cellular biochemistry · 2026Article
- Liver Fibrosis and Purinergic Signaling: Autocrine-Paracrine Role of ATP in Liver Damage.International journal of molecular sciences · 2026Review
- Abelmoschus manihot Polysaccharides Target the AMPK/Nrf2/HO-1 Signalling Pathway to Inhibit Macrophage M1 Polarisation and Hepatic Stellate Cell Activation Improving Liver Fibrosis in Mice.Journal of cellular and molecular medicine · 2026Article
- Systems pharmacology of traditional Chinese medicine in fibrosis: From multi-target mechanisms to translational validation.Chinese herbal medicines · 2026Review
- GSTM3 Knockdown Promotes Liver Fibrosis Reversal by Inhibiting Hepatic Stellate Cell Activation via PPARγ Signaling.Journal of clinical and translational hepatology · 2026Article
- Multiomics characterization of an alcohol-induced hepatocellular carcinoma mouse model.Lab animal · 2026Article
- New approach methodologies to model liver fibrosis in metabolic dysfunction-associated steatohepatitis.BMB reports · 2026Review
- Modeling hepatic fibrosis in TP53 knockout iPSC-derived human liver organoids.Molecular oncology · 2026Article
- Exploring the Inhibitory Effects of Compounds for the Treatment of Liver Fibrosis: A Computational and Microscopic Approach.Current pharmaceutical design · 2026Article
- Biliary atresia-related liver fibrosis.Frontiers in cell and developmental biology · 2026Review
- LGALS3 marks a pro-inflammatory, efferocytosis-low hepatic macrophage state and promotes hepatic stellate cell activation through the candidate receptor ANXA2 in liver cirrhosis.Frontiers in immunology · 2026Article
- Targeting Chemical-induced Hepatocellular Carcinoma: Ameliorative Potential of Natural Compounds with Focus on Beta-carbolines.Mini reviews in medicinal chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Liver fibrosis is a common result of liver injury owing to various kinds of chronic liver diseases. A deeper understanding of the pathophysiology of liver fibrosis and identifying potential therapeutic targets of liver fibrosis is important because liver fibrosis may progress to advanced liver diseases, such as cirrhosis and hepatocellular carcinoma. Despite numerous studies, the underlying mechanisms of liver fibrosis remain unclear. Mechanisms of the development and progression of liver fibrosis differ according to etiologies. Therefore, appropriate liver fibrosis models should be selected according to the purpose of the study and the type of underlying disease. Many in vivo animal and in vitro models have been developed to study liver fibrosis. However, there are no perfect preclinical models for liver fibrosis. In this review, we summarize the current in vivo and in vitro models for studying liver fibrosis and highlight emerging in vitro models, including organoids and liver-on-a-chip models. In addition, we discuss the mechanisms and limitations of each model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.